Abstracts tagged "cyclophosphamide"

Abstract Number: 126 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide as Rescue Therapy for Kawasaki Disease with Peripheral Vascular Disease: A Single Center Experience
Ugo Awa¹, Monica Bray ² and Marietta De Guzman ³, ¹Baylor College of Medicine, Houston, ²Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, ³Section of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, Texas
Background/Purpose: Kawasaki Disease (KD) is the most common systemic vasculitis affecting children 5 years and younger. With coronary vessel involvement, KD is now the most…
Abstract Number: 141 • 2020 Pediatric Rheumatology Symposium
Cyclophosphamide Use in Treatment of Refractory Kawasaki Disease: A Single Center Case Series of 10 Patients and Literature Review
Olha Halyabar¹, Mary Beth Son ², Margaret Chang ³ and Robert Sundel ¹, ¹Children's Hospital/Boston Medical Center, Boston, ²Boston Children's Hospital, Boston, Massachusetts, ³Boston Children's Hospital, Boston
Background/Purpose: Intravenous immunoglobulin (IVIG) effectively treats vasculitis of the coronary arteries in the large majority of Kawasaki Disease (KD) patients. However, approximately 25% of patients…
Abstract Number: 2632 • 2019 ACR/ARP Annual Meeting
Changing Trends in the Management of ANCA-associated Vasculitis at an Academic Medical Center
Sana Afroz¹ and Najia Shakoor ², ¹RUMC, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: For years, cyclophosphamide (CYC) has been the primary treatment for severe anca-associated vasculitides (AAV) and has significantly improved disease related mortality. In addition, maintenance…
Abstract Number: 2633 • 2019 ACR/ARP Annual Meeting
Efficacy of Remission Induction Regimens in Elderly Patients with ANCA-Associated Glomerulonephritis
Audrey Hopkins¹, Stanley Chu ², Philip Seo ³, Eric Gapud ¹, Brendan Antiochos ¹, Shaker Eid ¹, Jason Liebowitz ¹ and Duvuru Geetha ¹, ¹Johns Hopkins Bayview Medical Center, Baltimore, ²Johns Hopkins University, Baltimore, ³Johns Hopkins Medicine, Baltimore, MD
Background/Purpose: Induction regimens using either cyclophosphamide (CYC) or rituximab (RTX) have been shown to have similar efficacy and similar rates of adverse events in randomized…
Abstract Number: 812 • 2018 ACR/ARHP Annual Meeting
Inflammatory Stays Inflammatory: A Subgroup of Systemic Sclerosis Characterized By High Morbidity and Inflammatory Resistance to Cyclophosphamide
Aleksey Mitev¹, Daria Feldmann¹, Moritz Binder², Kim Möller³, Anna-Maria Kanne¹, Thomas Hügle⁴, Peter M. Villiger⁵, Reinhard Voll⁶, Stephanie Finzel¹ and Florian Kollert⁷, ¹Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ²Department of Internal Medicine, Mayo Clinic, Rochester, MN, ³Rheumatology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom, ⁴Rheumatology, University Hospital Lausanne (CHUV), Lausanne, Switzerland, ⁵Rheumatology and Clin Immunol, Bern, Switzerland, ⁶Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, ⁷Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland
Background/Purpose: Elevated levels of C-reactive protein (CRP) in systemic sclerosis (SSc) have been linked to early inflammatory stages of the disease. This study has been…
Abstract Number: 1728 • 2018 ACR/ARHP Annual Meeting
Pharmacokinetics of Cyclophosphamide in Scleroderma Treated By Cyclophosphamide Versus Transplantation
David Adams¹, Keith Sullivan², Ivan Spasojevic¹, Ping Fan¹, Mario Sampson³, Michael Cohen-Wolkowiez³, E. William St Clair⁴, Rob Woolson⁵, Jan Storek⁶, Mary Ellen Csuka⁷, Ashley Pinckney⁵, Beverly Welch⁸, Ellen Goldmuntz⁹, Daniel E. Furst¹⁰, Leslie Crofford¹¹, Lynette Keyes-Elstein¹², Maureen Mayes¹³, Peter McSweeney¹⁴ and Richard Nash¹⁴, ¹Medicine, Duke University Medical Center, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Pediatrics-Infectious Disease, Duke University Medical Center, Durham, NC, ⁴Rheumatology, Duke University Medical Center, Durham, NC, ⁵Rho Federal Systems, Inc., Chapel Hill, NC, ⁶University of Calgary, Calgary, AB, Canada, ⁷Medicine, Medical College of Wisconsin, Milwaukee, WI, ⁸National Institutes of Health, Bethesda, MD, ⁹NIAID, NIH, Bethesda, MD, ¹⁰University of Washington, Seattle, WA, ¹¹Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹²Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC, ¹³Rheumatology, University of Texas at Houston, Houston, TX, ¹⁴Colorado Blood Cancer Institute, Denver, CO
Background/Purpose: The pharmacokinetics (PK) of cyclophosphamide (CP) and its primary active metabolite, 4-hydroxycyclophosphamide (4-OH-CP) have not been adequately studied in scleroderma. The hypothesis of this…
Abstract Number: 1820 • 2018 ACR/ARHP Annual Meeting
Myeloablative Autologous Hematopoietic Stem Cell Transplantation for Severe Scleroderma: Long-Term Outcomes 6-11 Years after Entry on a Randomized Study Comparing Transplantation and Cyclophosphamide
Keith Sullivan¹, Ashley Pinckney², Ellen Goldmuntz³, Beverly Welch⁴, Dinesh Khanna⁵, Robert W. Simms⁶, Suzanne Kafaja⁷, George Georges⁸, Jan Storek⁹, Mary Ellen Csuka¹⁰, Richard Nash¹¹, Daniel E. Furst¹², Leslie Crofford¹³, Peter McSweeney¹¹, Maureen D. Mayes¹⁴ and Lynette Keyes-Elstein¹⁵, ¹Duke University Medical Center, Durham, NC, ²Rho Federal Systems, Inc., Chapel Hill, NC, ³NIAID, NIH, Bethesda, MD, ⁴National Institutes of Health, Bethesda, MD, ⁵Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, ⁶Rheumatology, Boston University School of Medicine, Boston, MA, ⁷David Geffen School of Medicine, UCLA, Los Angeles, CA, ⁸Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰Medicine, Medical College of Wisconsin, Milwaukee, WI, ¹¹Colorado Blood Cancer Institute, Denver, CO, ¹²University of Washington, Seattle, WA, ¹³Division of Rheumatology and Immunology, Vanderbilt University Medical Center, Nashville, TN, ¹⁴Rheumatology, University of Texas McGovern Medical School, Houston, TX, ¹⁵Clinical Statistics, Rho Federal Systems, Inc., Chapel Hill, NC
Background/Purpose: The Scleroderma: Cyclophosphamide or Transplantation (SCOT) trial demonstrated that for adults with severe scleroderma (ACR 1995 criteria) and internal organ involvement, myeloablative CD34+selected autologous…
Abstract Number: 2647 • 2018 ACR/ARHP Annual Meeting
Comparison of Low-Dose Intravenous Cyclophosphamide with Oral Mycophenolate Mofetil in the Treatment of Lupus Nephritis: Long Term Follow-up Data
Manish Rathi¹, Aman Sharma², Joyita Sharma³ and Krishan L Gupta³, ¹Department of Nephrology,, Postgraduate Institute of Medical Education and Research, Chandigarh, India, ²Clinical Immunology and Rheumatology Services, Department of Internal Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India, Chandigarh, India, ³Nephrology, Post Graduate Institute of Medical Education and Research, Chandigarrh, India
Background/Purpose: We present the long-term follow-up of patients with lupus nephritis who completed the randomized controlled trial on comparison of low-dose intravenous cyclophosphamide (IV CYC)…
Abstract Number: 2693 • 2018 ACR/ARHP Annual Meeting
What Is the Effect of Cyclophosphamide Iv Pulse Therapy in Patients with Diffuse Cutaneous Systemic Sclerosis on Skin Involvement: An Observational Study
Brigit Kersten, Nathan den Broeder, Frank van den Hoogen, Els van den Ende and Madelon Vonk, Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Patients with systemic sclerosis who have proximal skin involvement are classified as diffuse cutaneous systemic sclerosis (DcSSc). Patients with progressive skin involvement have worse prognosis.…
Abstract Number: 2742 • 2018 ACR/ARHP Annual Meeting
Rituximab Versus Cyclophosphamide for Vasculitic Neuropathy: A Patient Reported Outcomes Study
Aditi Patel¹, Kevin Byram², Yuxuan Jin³, Alexander Wu¹, Yuebing Li⁴, Leonard H. Calabrese⁵ and Rula A Hajj-Ali⁶, ¹Internal Medicine, Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic Foundation, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Department of Neurology, Cleveland Clinic, Cleveland, OH, ⁵Rheumatic & Immunologic Dis, Cleveland Clinic, Cleveland, OH, ⁶Rheumatic and Immunologic Disease, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose: Vasculitic neuropathy (VN) is a major complication of systemic vasculitis and contributes to morbidity, functional limitation, and health care utilization in affected patients. Patient…
Abstract Number: 749 • 2017 ACR/ARHP Annual Meeting
Treatment with Cyclophosphamide for Systemic Sclerosis-Interstitial Lung Disease Does Not Lead to a Sustained Improvement in Lung Function in Two Independent Cohorts
Elizabeth R. Volkmann¹, Donald P. Tashkin¹, Myung Sim¹, Ning Li², Dinesh Khanna³, Michael Roth⁴, Philip J. Clements⁴, Anna-Maria Hoffmann-Vold⁵, Daniel E. Furst¹, Grace Kim⁶, Jonathan Goldin¹ and Robert Elashoff⁷, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²Biomathematics, University of California, Los Angeles, Los Angeles, CA, ³University of Michigan, Ann Arbor, MI, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵Oslo University Hospital, Oslo, Norway, ⁶Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD) after 1 year in Scleroderma…
Abstract Number: 1684 • 2017 ACR/ARHP Annual Meeting
Effectiveness and Safety of Tacrolimus Following Intravenous Cyclophosphamide Pulse Therapy As the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease
Yuki Ichimura, Yasushi Kawaguchi, Kae Takagi, Akiko Tochimoto, Tomoaki Higuchi, Yasuhiro Katsumata and Hisashi Yamanaka, Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Systemic sclerosis (SSc) is the disease characterized by organ fibrosis with unknown etiology, and pulmonary involvement is one of major cause of death. However,…
Abstract Number: 2603 • 2017 ACR/ARHP Annual Meeting
Induction of Lupus Nephritisin in Real Situation: Cyclophosphamide or Mycophenolate Mofetil?
Gabriela Munhoz¹, Maira Lacerda¹, Michelle Lopes¹, Eduardo Ferreira Borba¹, Luciana Seguro² and Eloisa Bonfa³, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Divison, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Low-dose intravenous cyclophosphamide (Euro-lupus) and Mycophenolate mofetil (MMF) are well established in lupus nephritis induction therapy, but there are few studies comparing both treatments.…
Abstract Number: 2624 • 2017 ACR/ARHP Annual Meeting
A Renal Biopsy Should Not Delay Treatment Initiation in Suspected Lupus Nephritis
Astrid Baumann¹, Angela Pakozdi², Andrea Cove-Smith², Debasish Pyne², Michael Sheaff¹ and Ravindra Rajakariar², ¹Barts Lupus Centre, London, United Kingdom, ²Barts Lupus Centre, Barts Health NHS Trust, London, United Kingdom
Background/Purpose: Renal biopsies are considered the gold standard in diagnosing lupus nephritis (LN). ALMS (1), the largest randomized trial in LN, reported the non-inferiority of…
Abstract Number: 31 • 2017 ACR/ARHP Annual Meeting
Single Cell Analysis Revealed That the Response to Cyclophosphamide Therapy Is Regulated By B Cells in Systemic Sclerosis-Associated Interstitial Lung Disease
Satoshi Ebata¹, Ayumi Yoshizaki², Takemichi Fukasawa¹, Kouki Nakamura¹, Maiko Hirakawa¹, Takashi Yamashita¹, Shunsuke Miura³, Ryosuke Saigusa¹, Megumi Hirabayashi¹, Asako Yoshizaki¹, Kaname Akamata¹, Yoshihide Asano⁴, Yutaka Kazoe⁵, Kazuma Mawatari⁵, Takehiko Kitamori⁵ and Shinichi Sato⁶, ¹Dermatology, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ²Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁴Applied Chemistry, University of Tokyo, Graduate School of Medicine, Tokyo, Japan, ⁵Applied Chemistry, University of Tokyo, Graduate School of Engineering, Tokyo, Japan, ⁶Department of Dermatology, Graduate School of Medicine, The University of Tokyo, Bunkyo-ku, Japan
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disease characterized by fibrosis of several organs. SSc-associated interstitial lung disease (ILD) is a frequent and severe complication…